Achilles Therapeutics PLC (ACHL) - Market Cap to Net Income Ratio

Corporate emblem and logo of Achilles Therapeutics plc (ACHL)

Achilles Therapeutics (ACHL) creates personalized tumor combat methods, leveraging patent-protected AI technologies and strict FDA oversight. This chart of the market valuation with the -0.90 metric demonstrates the business value. The high scientific competence of the executives enables efficient capital allocation, accelerating the transition of innovative cell products to the final stages of medical trials.

ACHL achillestx.com: Price to Earnings Ratio in the range 07/04/2022 - 03/29/2025

Comprehensive metric breakdowns and analytics for Achilles Therapeutics PLC (ACHL)

Comprehensive company analysis:Achilles Therapeutics PLC
Signature product of Achilles Therapeutics plc

The estimated P/E dynamics of Achilles Therapeutics (ACHL) depend on the ratio of market capitalization to net income. This ratio determines the cost of one dollar of earnings, helping to assess the asset's degree of overboughtness. For Achilles Therapeutics (ACHL), this metric reflects investments in bioreactor automation to eliminate human error during T-cell creation. The efficiency of robotization directly impacts future margins. Analyzing the company's estimated P/E allows for a comparison of current innovation costs against market expectations.